Skip to content

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city.

MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and dementia patients.

According to the Alzheimer’s Association, 5.8 million Americans have the disease, a degenerative brain disorder that affects a person’s memory and thinking skills. While there are drugs that help ease symptoms, they do not change the course of the disease.

Albert Gutierrez, CEO of MedPharm, sees Alzheimer’s as “one of the biggest things that’s plaguing our country now and in the future.” That’s why he’s excited about cannabis’ potential to treat it.

Read Full Article Here

Stories you may be interested in

Scientists Discover Two New Cannabinoids

The plant Cannabis sativa produces more than 400 chemicals, but only one, THC, gets you high. Or so it seems. A group of Italian researchers announced on December 30th the discovery of two new cannabinoids, chemicals produced by weed like THC and CBD. The first, tetrahydrocannabiphorol (THCP), is allegedly 30 times more potent than THC, they claim.…
Read More

Colorado looks to medical marijuana to ease opioid crisis

As the nation grapples with an opioid crisis that kills more than 130 people every day, Colorado thinks a solution may lie in a joint, a vape pen or a topical. On Friday, it becomes the third state in the nation after New York and Illinois to allow doctors to recommend medical marijuana for any condition…
Read More

Cannabis for Treating IBD: Hope or Hype?

Nausea, abdominal pain and changes in appetite. These are all things that can significantly impact one’s wellbeing if left untreated, yet they have all shown marked improvements when associated with cannabis. Yet, less is known about the effects of cannabis on inflammatory bowel disease, or IBD, a chronic inflammatory condition that impacts the gastrointestinal tract…
Read More

Older adults and medical marijuana: Reduced stigma and increased use

As a primary care doctor who has incorporated medical cannabis into his practice, it is notable how many silver-haired patients are coming in to discuss the pros and cons of a trial of medical cannabis. These patients range from people in their 60s with kidney failure who can no longer take certain pain medications but…
Read More

Three Key Voices in the Medical Marijuana Industry

As medical marijuana programs continue to expand throughout the United States, it is important to recognize some of the key voices throughout the industry that got us here. These individuals range from researches to physicians and even to patients who started their own advocacy group. Keep reading to learn about just three of the many…
Read More

REGISTRATION NOW OPEN: Arfinn Med Medical Cannabis Efficacy Portal for Licensed Medical Professionals

Arfinn Med, the first clinician-based medical professional and patient efficacy portal for medical cannabis treatments, is now open for registrations from licensed medical professionals. The free collaborative portal allows medical professionals to register, share, research and communicate HIPAA-compliant benchmark data for medical cannabis treatments. As a free tool for physicians, Arfinn Med offers a new…
Read More

Leave a Comment

You must be logged in to post a comment.